A non-smoking 45-year-old white man presented with a globus sensation worsened by lying down, with no complaints of hoarseness or dysphonia. He denied fever, fatigue, cough, chest pain, sweats, weight loss, reflux, arthralgias, myalgias and rash. He also denied exposure to asbestosis, beryllium, silica, HIV or tuberculosis, but he reported a recent cat bite. Physical examination revealed normal vital signs, no cervical or supraclavicular lympadenopathy and a normal cardiorespiratory system. He was referred to the otolaryngology department. Laryngoscopy revealed right vocal cord paralysis. A CT scan of the neck/chest identified diffuse mediastinal lymphadenopathy without parenchymal changes (figures 1 and 2).
A purified protein derivative test was negative. Endobronchial ultrasound (EBUS)-directed transbronchial needle aspirations (TBNA) were performed of the paratracheal and subcarinal lymph nodes (figure 3). Diagnostic bronchoscopy revealed no endobronchial lesions or mucosal abnormalities. Acid-fast bacilli studies were negative and flow cytometry detected no monoclonal lymphocytes. Bacterial and fungal cultures, cryptococcal/ histoplasma antigen, HIV and Bartonella serology were negative. ACE was 31 U/l (reference range 9e67 U/l). Pulmonary function testing revealed mild decreased diffusion capacity but was otherwise normal. Empirical steroid therapy failed to provide benefit and mediastinoscopic right paratracheal lymphadenectomy was subsequently conducted (figure 4).
QUESTION

What is the diagnosis?
See page 231 for answer Michael Boyd, Subramanian Malaisamy, Susanti Ie, Edmundo Rubio promoting AE. AIPF also gives new insight into the key role of locoregional factors in the expansion of pulmonary fibrosis. TLCO may not be adapted to evaluate the severity of this particular form of IPF. Further studies are needed to assess more clearly the frequency and specific risk factors for AIPF and to determine the real impact of this form of IPF on clinical practice.
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